Unknown

Dataset Information

0

Small molecules disaggregate alpha-synuclein and prevent seeding from patient brain-derived fibrils.


ABSTRACT: The amyloid aggregation of alpha-synuclein within the brain is associated with the pathogenesis of Parkinson's disease (PD) and other related synucleinopathies, including multiple system atrophy (MSA). Alpha-synuclein aggregates are a major therapeutic target for treatment of these diseases. We identify two small molecules capable of disassembling preformed alpha-synuclein fibrils. The compounds, termed CNS-11 and CNS-11g, disaggregate recombinant alpha-synuclein fibrils in vitro, prevent the intracellular seeded aggregation of alpha-synuclein fibrils, and mitigate alpha-synuclein fibril cytotoxicity in neuronal cells. Furthermore, we demonstrate that both compounds disassemble fibrils extracted from MSA patient brains and prevent their intracellular seeding. They also reduce in vivo alpha-synuclein aggregates in C. elegans. Both compounds also penetrate brain tissue in mice. A molecular dynamics-based computational model suggests the compounds may exert their disaggregating effects on the N terminus of the fibril core. These compounds appear to be promising therapeutic leads for targeting alpha-synuclein for the treatment of synucleinopathies.

SUBMITTER: Murray KA 

PROVIDER: S-EPMC9963379 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Small molecules disaggregate alpha-synuclein and prevent seeding from patient brain-derived fibrils.

Murray Kevin A KA   Hu Carolyn J CJ   Pan Hope H   Lu Jiahui J   Abskharon Romany R   Bowler Jeannette T JT   Rosenberg Gregory M GM   Williams Christopher K CK   Elezi Gazmend G   Balbirnie Melinda M   Faull Kym F KF   Vinters Harry V HV   Seidler Paul M PM   Eisenberg David S DS  

Proceedings of the National Academy of Sciences of the United States of America 20230209 7


The amyloid aggregation of alpha-synuclein within the brain is associated with the pathogenesis of Parkinson's disease (PD) and other related synucleinopathies, including multiple system atrophy (MSA). Alpha-synuclein aggregates are a major therapeutic target for treatment of these diseases. We identify two small molecules capable of disassembling preformed alpha-synuclein fibrils. The compounds, termed CNS-11 and CNS-11g, disaggregate recombinant alpha-synuclein fibrils in vitro, prevent the in  ...[more]

Similar Datasets

| S-EPMC9525671 | biostudies-literature
| S-EPMC6736640 | biostudies-literature
| S-EPMC9481533 | biostudies-literature
| S-EPMC7425896 | biostudies-literature
| EMPIAR-11094 | biostudies-other
| S-EPMC6879756 | biostudies-literature
| S-EPMC7949133 | biostudies-literature
| EMPIAR-11095 | biostudies-other
| S-EPMC5520965 | biostudies-literature
| S-EPMC8946814 | biostudies-literature